Skip to main content

Published locations for Cost is the main hurdle to broad use of caplacizumab for TTP

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Cost is the main hurdle to broad use of caplacizumab for TTP

User login

  • Reset your password
  • /content/cost-main-hurdle-broad-use-caplacizumab-ttp
  • /hematologynews/article/233062/thrombosis/cost-main-hurdle-broad-use-caplacizumab-ttp
  • /internalmedicinenews/article/233062/thrombosis/cost-main-hurdle-broad-use-caplacizumab-ttp
  • /hospitalist/article/233062/thrombosis/cost-main-hurdle-broad-use-caplacizumab-ttp
  • /jcomjournal/article/233062/thrombosis/cost-main-hurdle-broad-use-caplacizumab-ttp
  • /hematology-oncology/article/233062/thrombosis/cost-main-hurdle-broad-use-caplacizumab-ttp
  • /ecardiologynews/article/233062/thrombosis/cost-main-hurdle-broad-use-caplacizumab-ttp
  • /cardiology/article/233062/thrombosis/cost-main-hurdle-broad-use-caplacizumab-ttp
  • /internalmedicine/article/233062/thrombosis/cost-main-hurdle-broad-use-caplacizumab-ttp